Neutrophils and lipocalin-2 in triglyceride-glucose body mass index-related cardiometabolic risk among patients with rheumatoid arthritis: a multicenter study
Abstract
Cardiometabolic risk is increased in rheumatoid arthritis (RA), but early risk may remain unrecognized before overt metabolic abnormalities emerge. Whether neutrophil-associated inflammation can help identify this latent risk and its potential molecular link remains unclear. We analyzed 1,028 patients with RA to examine factors associated with elevated triglyceride-glucose body mass index (TyG-BMI) and developed machine learning models using routinely available clinical variables to distinguish patients in the highest (Q4) and lowest (Q1) TyG-BMI quartiles. An exploratory 12-month follow-up assessment was also conducted. Transcriptomic analyses identified candidate neutrophil-related markers, which were subsequently evaluated in an independent prospective multicenter cohort of 502 patients. Neutrophil count remained independently associated with elevated TyG-BMI after full multivariable adjustment and additional adjustment for antirheumatic medication use (OR = 1.17, 95% CI 1.08–1.27; P < 0.001). The selected logistic regression model achieved an AUC of 0.829 in the internal validation set for distinguishing the Q4 and Q1 TyG-BMI groups. Among patients without overt cardiometabolic disease and with normal baseline metabolic indicators, newly reported physician-diagnosed cardiometabolic conditions during the 12-month follow-up were reported by 21.3% of Q4 participants and 10.7% of Q1 participants (RR = 1.98, 95% CI 1.02–3.87; P = 0.044). Transcriptomic analyses identified lipocalin-2 (LCN2) as a candidate molecular link. In the prospective cohort, adding LCN2 modestly increased the AUC from 0.799 to 0.812 (DeLong P = 0.286); net reclassification improvement (NRI) was not significant, whereas integrated discrimination improvement (IDI) improved significantly ( P = 0.008). Exploratory mediation analysis yielded an estimated mediated proportion of 25.8% ( P < 0.001). Neutrophil-associated inflammation may help identify latent cardiometabolic risk in RA, with LCN2 emerging as a potential molecular link and complementary biomarker.
Related
- Triglyceride-glucose index combined with DAS28-ESR predicts cardiovascular disease risk in patients with rheumatoid arthritis: a national multicenter cohort study
- Comparison analysis of the triglyceride-glucose index, triglyceride-glucose and frailty index in cardiovascular disease and mortality association among patients with rheumatoid arthritis: A population-based cohort study.
- Dose-Response Relationship Between Triglyceride Glucose-Waist Height Ratio Index and Cardiometabolic Multimorbidity Among Chinese Middle-Aged and Older People.
- Waist-centered triglyceride-glucose markers and inflammation in relation to incident cardiometabolic multimorbidity: a multinational pooled analysis of five aging cohorts
- Triglyceride–HDL cholesterol–glucose body index and cardiometabolic multimorbidity: evidence from a national longitudinal cohort and a subplateau health-screening population
BibTeX
@article{xin2026neutrophils,
title = {{Neutrophils and lipocalin-2 in triglyceride-glucose body mass index-related cardiometabolic risk among patients with rheumatoid arthritis: a multicenter study}},
author = {Tong Xin and Che Wang and Yurui Wang and Fan Gong and Yanxia Zhao and Jingjing He and Xiaoping Wang and Daqing Nie and Guorong Jin and Aijing Liu},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73963-0},
url = {https://www.nature.com/articles/s41598-026-73963-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Neutrophils and lipocalin-2 in triglyceride-glucose body mass index-related cardiometabolic risk among patients with rheumatoid arthritis: a multicenter study
AU - Tong Xin
AU - Che Wang
AU - Yurui Wang
AU - Fan Gong
AU - Yanxia Zhao
AU - Jingjing He
AU - Xiaoping Wang
AU - Daqing Nie
AU - Guorong Jin
AU - Aijing Liu
PY - 2026
DA - 2026/10/08
JO - Scientific Reports
DO - 10.1038/s41598-026-73963-0
UR - https://www.nature.com/articles/s41598-026-73963-0
AB - Cardiometabolic risk is increased in rheumatoid arthritis (RA), but early risk may remain unrecognized before overt metabolic abnormalities emerge. Whether neutrophil-associated inflammation can help identify this latent risk and its potential molecular link remains unclear. We analyzed 1,028 patients with RA to examine factors associated with elevated triglyceride-glucose body mass index (TyG-BMI) and developed machine learning models using routinely available clinical variables to distinguish patients in the highest (Q4) and lowest (Q1) TyG-BMI quartiles. An exploratory 12-month follow-up assessment was also conducted. Transcriptomic analyses identified candidate neutrophil-related markers, which were subsequently evaluated in an independent prospective multicenter cohort of 502 patients. Neutrophil count remained independently associated with elevated TyG-BMI after full multivariable adjustment and additional adjustment for antirheumatic medication use (OR = 1.17, 95% CI 1.08–1.27; P < 0.001). The selected logistic regression model achieved an AUC of 0.829 in the internal validation set for distinguishing the Q4 and Q1 TyG-BMI groups. Among patients without overt cardiometabolic disease and with normal baseline metabolic indicators, newly reported physician-diagnosed cardiometabolic conditions during the 12-month follow-up were reported by 21.3% of Q4 participants and 10.7% of Q1 participants (RR = 1.98, 95% CI 1.02–3.87; P = 0.044). Transcriptomic analyses identified lipocalin-2 (LCN2) as a candidate molecular link. In the prospective cohort, adding LCN2 modestly increased the AUC from 0.799 to 0.812 (DeLong P = 0.286); net reclassification improvement (NRI) was not significant, whereas integrated discrimination improvement (IDI) improved significantly ( P = 0.008). Exploratory mediation analysis yielded an estimated mediated proportion of 25.8% ( P < 0.001). Neutrophil-associated inflammation may help identify latent cardiometabolic risk in RA, with LCN2 emerging as a potential molecular link and complementary biomarker.
SN - 2045-2322
ER -